DYNAVAX TECHNOLOGIES CORP (DVAX)
Data as of , from SEC Form 4 filings.
See up to 3 months of DVAX. The 7-day demo opens the 1M and 3M ranges and puts DVAX on your watchlist.
Start 7-day demoLatest DVAX insider trades
About DYNAVAX TECHNOLOGIES CORP (DVAX)
DYNAVAX TECHNOLOGIES CORP files with the SEC under CIK 0001029142 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
DVAX Form 4 activity by transaction type, last 90 days
No Form 4 activity for DVAX in the last 90 days.
DVAX insider transactions (Form 4)
12525 Form 4 filings on record, the earliest from May 12, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Deep Track Biotechnology Master Fund, Ltd. | Other | Common Stock, par value $0.001 per share | 15,726,349 | - footnote F1 | - | |
| ||||||
| Ryan Spencer - Officer | Other | Common Stock | 379,620 | - footnote F3 | - | |
| Ryan Spencer - Officer | Grant or award | Common Stock - Performance Stock Units | 165,000 | - footnote F4 | - | |
| Ryan Spencer - Officer | Derivative | Common Stock - Performance Stock Units | 165,000 | - footnote F5 | - | |
| Ryan Spencer - Officer | Grant or award | Common Stock - Performance Stock Units | 136,000 | - footnote F6 | - | |
| Ryan Spencer - Officer | Derivative | Common Stock - Performance Stock Units | 136,000 | - footnote F5 | - | |
| Ryan Spencer - Officer | Derivative | Stock Option (Right to Buy) | 50,000 | - footnote F7 | - | |
| Ryan Spencer - Officer | Derivative | Stock Option (Right to Buy) | 400,000 | - footnote F7 | - | |
| Ryan Spencer - Officer | Derivative | Stock Option (Right to Buy) | 130,000 | - footnote F7 | - | |
| Ryan Spencer - Officer | Derivative | Stock Option (Right to Buy) | 250,000 | - footnote F7 | - | |
| Ryan Spencer - Officer | Derivative | Stock Option (Right to Buy) | 350,000 | - footnote F7 | - | |
| Ryan Spencer - Officer | Derivative | Stock Option (Right to Buy) | 280,000 | - footnote F7 | - | |
| Ryan Spencer - Officer | Derivative | Stock Option (Right to Buy) | 231,000 | - footnote F7 | - | |
| Ryan Spencer - Officer | Derivative | Stock Option (Right to Buy) | 225,000 | - footnote F7 | - | |
| Ryan Spencer - Officer | Derivative | Restricted Stock Units | 55,000 | - footnote F10 | - | |
| Ryan Spencer - Officer | Derivative | Restricted Stock Units | 90,667 | - footnote F10 | - | |
| ||||||
| John L. Slebir - Officer | Other | Common Stock | 69,634 | - footnote F3 | - | |
| John L. Slebir - Officer | Grant or award | Common Stock - Performance Stock Units | 50,000 | - footnote F4 | - | |
| John L. Slebir - Officer | Derivative | Common Stock - Performance Stock Units | 50,000 | - footnote F5 | - | |
| John L. Slebir - Officer | Grant or award | Common Stock - Performance Stock Units | 42,424 | - footnote F6 | - | |
| John L. Slebir - Officer | Derivative | Common Stock - Performance Stock Units | 42,424 | - footnote F5 | - | |
| John L. Slebir - Officer | Derivative | Stock Option (Right to Buy) | 300,000 | - footnote F7 | - | |
| John L. Slebir - Officer | Derivative | Stock Option (Right to Buy) | 80,000 | - footnote F7 | - | |
| John L. Slebir - Officer | Derivative | Stock Option (Right to Buy) | 88,000 | - footnote F7 | - | |
| John L. Slebir - Officer | Derivative | Stock Option (Right to Buy) | 70,000 | - footnote F7 | - | |
| John L. Slebir - Officer | Derivative | Stock Option (Right to Buy) | 70,000 | - footnote F7 | - | |
| John L. Slebir - Officer | Derivative | Restricted Stock Units | 16,666 | - footnote F10 | - | |
| John L. Slebir - Officer | Derivative | Restricted Stock Units | 28,283 | - footnote F10 | - | |
| ||||||
| Joseph Anthony Metzinger - Officer | Other | Common Stock | 7,129 | - footnote F3 | - | |
| Joseph Anthony Metzinger - Officer | Derivative | Stock Option (Right to Buy) | 31,500 | - footnote F5 | - | |
| Joseph Anthony Metzinger - Officer | Derivative | Restricted Stock Units | 25,455 | - footnote F7 | - | |
| ||||||
| Kelly Macdonald - Officer | Derivative | Stock Option (Right to Buy) | 65,000 | - footnote F7 | - | |
| Kelly Macdonald - Officer | Derivative | Stock Option (Right to Buy) | 70,000 | - footnote F7 | - | |
| Kelly Macdonald - Officer | Derivative | Restricted Stock Units | 15,476 | - footnote F10 | - | |
| Kelly Macdonald - Officer | Derivative | Restricted Stock Units | 28,283 | - footnote F10 | - | |
| Kelly Macdonald - Officer | Other | Common Stock | 60,204 | - footnote F3 | - | |
| Kelly Macdonald - Officer | Grant or award | Common Stock - Performance Stock Units | 46,430 | - footnote F4 | - | |
| Kelly Macdonald - Officer | Derivative | Common Stock - Performance Stock Units | 46,430 | - footnote F5 | - | |
| Kelly Macdonald - Officer | Grant or award | Common Stock - Performance Stock Units | 42,424 | - footnote F6 | - | |
| Kelly Macdonald - Officer | Derivative | Common Stock - Performance Stock Units | 42,424 | - footnote F5 | - | |
| Kelly Macdonald - Officer | Derivative | Stock Option (Right to Buy) | 350,000 | - footnote F7 | - | |
| Kelly Macdonald - Officer | Derivative | Stock Option (Right to Buy) | 90,500 | - footnote F7 | - | |
| Kelly Macdonald - Officer | Derivative | Stock Option (Right to Buy) | 100,000 | - footnote F7 | - | |
| ||||||
| Scott Dunseth Myers | Other | Common Stock | 3,800 | - footnote F3 | - | |
| Scott Dunseth Myers | Derivative | Common Stock - Restricted Stock Units | 31,204 | - footnote F4 | - | |
| Scott Dunseth Myers | Derivative | Stock Option (Right to Buy) | 45,000 | - footnote F5 | - | |
| Scott Dunseth Myers | Derivative | Stock Option (Right to Buy) | 16,875 | - footnote F5 | - | |
| Scott Dunseth Myers | Derivative | Stock Option (Right to Buy) | 22,500 | - footnote F5 | - | |
| Scott Dunseth Myers | Derivative | Stock Option (Right to Buy) | 22,500 | - footnote F5 | - | |
| Scott Dunseth Myers | Derivative | Stock Option (Right to Buy) | 28,500 | - footnote F5 | - | |
| ||||||
| Emilio Emini | Derivative | Common Stock - Restricted Stock Units | 10,075 | - footnote F3 | - | |
| Emilio Emini | Derivative | Stock Option (Right to Buy) | 42,750 | - footnote F4 | - | |
| Emilio Emini | Derivative | Stock Option (Right to Buy) | 7,125 | - footnote F4 | - | |
| ||||||
| Daniel L. Kisner | Other | Common Stock | 1,500 | - footnote F3 | - | |
| Daniel L. Kisner | Derivative | Common Stock - Restricted Stock Units | 21,829 | - footnote F4 | - | |
| Daniel L. Kisner | Derivative | Stock Option (Right o Buy) | 15,000 | - footnote F5 | - | |
| Daniel L. Kisner | Derivative | Stock Option (Right to Buy) | 25,000 | - footnote F5 | - | |
| Daniel L. Kisner | Derivative | Stock Option (Right to Buy) | 25,000 | - footnote F5 | - | |
| Daniel L. Kisner | Derivative | Stock Option (Right to Buy) | 22,500 | - footnote F5 | - | |
| Daniel L. Kisner | Derivative | Stock Option (Right to Buy) | 22,500 | - footnote F5 | - | |
| Daniel L. Kisner | Derivative | Stock Option (Right to Buy) | 22,500 | - footnote F5 | - | |
| Daniel L. Kisner | Derivative | Stock Option (Right to Buy) | 28,500 | - footnote F5 | - | |
| ||||||
| Elaine D. Sun | Derivative | Common Stock - Restricted Stock Units | 29,865 | - footnote F3 | - | |
| Elaine D. Sun | Derivative | Stock Option (Right to Buy) | 45,000 | - footnote F4 | - | |
| Elaine D. Sun | Derivative | Stock Option (Right to Buy) | 11,250 | - footnote F4 | - | |
| Elaine D. Sun | Derivative | Stock Option (Right to Buy) | 22,500 | - footnote F4 | - | |
| Elaine D. Sun | Derivative | Stock Option (Right to Buy) | 22,500 | - footnote F4 | - | |
| Elaine D. Sun | Derivative | Stock Option (Right to Buy) | 28,500 | - footnote F4 | - | |
| ||||||
| Brent Macgregor | Derivative | Common Stock - Restricted Stock Units | 21,829 | - footnote F3 | - | |
| Brent Macgregor | Derivative | Stock Option (Right to Buy) | 50,000 | - footnote F4 | - | |
| Brent Macgregor | Derivative | Stock Option (Right to Buy) | 25,000 | - footnote F4 | - | |
| Brent Macgregor | Derivative | Stock Option (Right to Buy) | 22,500 | - footnote F4 | - | |
| Brent Macgregor | Derivative | Stock Option (Right to Buy) | 22,500 | - footnote F4 | - | |
| Brent Macgregor | Derivative | Stock Option (Right to Buy) | 22,500 | - footnote F4 | - | |
| Brent Macgregor | Derivative | Stock Option (Right to Buy) | 28,500 | - footnote F4 | - | |
| ||||||
| Lauren P. Silvernail | Derivative | Common Stock - Restricted Stock Units | 10,075 | - footnote F3 | - | |
| Lauren P. Silvernail | Derivative | Stock Option (Right to Buy) | 42,750 | - footnote F4 | - | |
| Lauren P. Silvernail | Derivative | Stock Option (Right to Buy) | 7,125 | - footnote F4 | - | |
| ||||||
| Francis Cano | Derivative | Common Stock - Restricted Stock Units | 42,663 | - footnote F3 | - | |
| Francis Cano | Derivative | Stock Option (Right to Buy) | 25,000 | - footnote F4 | - | |
| Francis Cano | Derivative | Stock Option (Right to Buy) | 25,000 | - footnote F4 | - | |
| Francis Cano | Derivative | Stock Option (Right to Buy) | 22,500 | - footnote F4 | - | |
| Francis Cano | Derivative | Stock Option (Right to Buy) | 22,500 | - footnote F4 | - | |
| Francis Cano | Derivative | Stock Option (Right to Buy) | 22,500 | - footnote F4 | - | |
| Francis Cano | Derivative | Stock Option (Right to Buy) | 28,500 | - footnote F4 | - | |
| ||||||
| Derivative | Stock Option (Right to Buy) | 150,000 | - footnote F7 | - | ||
| Other | Common Stock | 63,334 | - footnote F3 | - | ||
| Grant or award | Common Stock - Performance Stock Units | 67,860 | - footnote F4 | - | ||
| Derivative | Common Stock - Performance Stock Units | 67,860 | - footnote F5 | - | ||
| Grant or award | Common Stock - Performance Stock Units | 56,364 | - footnote F6 | - | ||
| Derivative | Common Stock - Performance Stock Units | 56,364 | - footnote F5 | - | ||
| Derivative | Stock Option (Right to Buy) | 150,000 | - footnote F7 | - | ||
| Derivative | Stock Option (Right to Buy) | 150,000 | - footnote F7 | - | ||
| Derivative | Stock Option (Right to Buy) | 150,000 | - footnote F7 | - | ||
| Derivative | Stock Option (Right to Buy) | 95,000 | - footnote F7 | - | ||
| Derivative | Stock Option (Right to Buy) | 93,000 | - footnote F7 | - | ||
| Derivative | Restricted Stock Units | 22,620 | - footnote F10 | - | ||
| Derivative | Restricted Stock Units | 37,576 | - footnote F10 | - | ||
| ||||||
| Option exercise | Common Stock | 20,000 | $6.81 | $136K | ||
| Option exercise | Common Stock | 94,000 | $10.47 | $984K | ||
| Open-market sale | Common Stock | 114,000 | $15.64 footnote F2 | $1.78M | ||
| Option exercise | Stock Option (Right to Buy) | 20,000 | - footnote F4 | - | ||
| Option exercise | Stock Option (Right to Buy) | 85,655 | - footnote F4 | - | ||
| Option exercise | Stock Option (Right to Buy) | 8,345 | - footnote F4 | - | ||
| ||||||
| Scott Dunseth Myers - Director | Open-market purchase | Common Stock | 3,800 | $10.82 | $41K | |
| Deep Track Biotechnology Master Fund, Ltd. | Open-market sale | Common Stock, par value $0.001 per share | 1,094,994 | $11.03 | $12.08M | |
| Deep Track Biotechnology Master Fund, Ltd. | Open-market sale | Common Stock, par value $0.001 per share | 970,143 | $10.59 | $10.27M | |
| Lauren P. Silvernail - Director | Grant or award | Common Stock | 1,439 | $0.00 | - | |
| Lauren P. Silvernail - Director | Grant or award | Stock Option (Right to Buy) | 7,125 | $0.00 | - | |
| Daniel L. Kisner - Director | Grant or award | Common Stock | 5,758 | $0.00 | - | |
| Daniel L. Kisner - Director | Grant or award | Stock Option (Right to Buy) | 28,500 | $0.00 | - | |
| Scott Dunseth Myers - Director | Grant or award | Common Stock | 5,758 | $0.00 | - | |
| Scott Dunseth Myers - Director | Grant or award | Stock Option (Right to Buy) | 28,500 | $0.00 | - | |
| Peter R. Paradiso - Director | Grant or award | Common Stock | 5,758 | $0.00 | - | |
| Peter R. Paradiso - Director | Grant or award | Stock Option (Right to Buy) | 28,500 | $0.00 | - | |
| Emilio Emini - Director | Grant or award | Common Stock | 1,439 | $0.00 | - | |
| Emilio Emini - Director | Grant or award | Stock Option (Right to Buy) | 7,125 | $0.00 | - | |
| Elaine D. Sun - Director | Grant or award | Common Stock | 5,758 | $0.00 | - | |
| Elaine D. Sun - Director | Grant or award | Stock Option (Right to Buy) | 28,500 | $0.00 | - | |
| Brent Macgregor - Director | Grant or award | Common Stock | 5,758 | $0.00 | - | |
| Brent Macgregor - Director | Grant or award | Stock Option (Right to Buy) | 28,500 | $0.00 | - | |
| Francis Cano - Director | Grant or award | Common Stock | 5,758 | $0.00 | - | |
| Francis Cano - Director | Grant or award | Stock Option (Right to Buy) | 28,500 | $0.00 | - | |
| Joseph Anthony Metzinger - Officer | Grant or award | Option (Right to Buy) | 31,500 | - | - | |
| Joseph Anthony Metzinger - Officer | Grant or award | Restricted Stock Unit | 38,182 | - | - | |
DVAX insider trading FAQ
What is the latest insider trade for DVAX?
DYNAVAX TECHNOLOGIES CORP (DVAX) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-02-11. The full record for DVAX runs to 25 Form 4 filings, the earliest from 2025-05-12. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying DVAX stock?
No insider purchases of DVAX were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling DVAX stock?
No insider sales of DVAX were filed in the last 90 days. 3 sales are on record for this company.
Where can I see DVAX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects DVAX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Deep Track Biotechnology Master Fund, Ltd. view on EDGAR
- - Ryan Spencer view on EDGAR
- - John L. Slebir view on EDGAR
- - Joseph Anthony Metzinger view on EDGAR
- - Kelly Macdonald view on EDGAR
- - Scott Dunseth Myers view on EDGAR
- - Emilio Emini view on EDGAR
- - Daniel L. Kisner view on EDGAR
- - Elaine D. Sun view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where DVAX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow DVAX with a 7-day demo
- DVAX on your watchlist
- Every DVAX Form 4 filing on record
- Up to 3 months of DVAX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive